| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J J Canales, C Capper-Loup, D Hu, E S Choe, U Upadhyay, A M Graybie. Shifts in striatal responsivity evoked by chronic stimulation of dopamine and glutamate systems. Brain : a journal of neurology. vol 125. issue Pt 10. 2002-10-29. PMID:12244091. |
the model provides a framework for analysing the neurological alterations associated with disorders of the basal ganglia and their treatment with pharmacotherapies affecting dopamine and glutamate neurotransmitter systems. |
2002-10-29 |
2023-08-12 |
rat |
| L A Macki. Understanding Parkinson's disease: detection and early disease management. Lippincott's primary care practice. vol 4. issue 6. 2002-10-08. PMID:11933373. |
parkinson's disease (pd) is a common, debilitating, neurodegenerative disorder characterized by neuronal loss within the basal ganglia and insufficient levels of the neurotransmitter dopamine. |
2002-10-08 |
2023-08-12 |
Not clear |
| Lynette D Fairbanks, Gabriella Jacomelli, Vanna Micheli, Tina Slade, H Anne Simmond. Severe pyridine nucleotide depletion in fibroblasts from Lesch-Nyhan patients. The Biochemical journal. vol 366. issue Pt 1. 2002-10-08. PMID:11996669. |
nad plus atp depletion in developing brain could restrict dna repair, leading to neuronal damage/loss by apoptosis, and, with gtp depletion, affect neurotransmitter synthesis and basal ganglia dopaminergic neuronal systems. |
2002-10-08 |
2023-08-12 |
human |
| T R Guilart. Is methamphetamine abuse a risk factor in parkinsonism? Neurotoxicology. vol 22. issue 6. 2002-07-17. PMID:11829406. |
the molecular basis of pd is the nearly complete loss of the neurotransmitter dopamine (da) in the basal ganglia (caudate/putamen). |
2002-07-17 |
2023-08-12 |
human |
| Hagai Bergman, Günther Deusch. Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. Movement disorders : official journal of the Movement Disorder Society. vol 17 Suppl 3. 2002-05-10. PMID:11948753. |
however, the present evidence supports the view that the basal ganglia loops are influenced by other neuronal structures and systems and that the tuning of these loops by cerebello-thalamic mechanisms and by other modulator neurotransmitter systems entrain the abnormal synchronized oscillations. |
2002-05-10 |
2023-08-12 |
Not clear |
| M V Johnston, O H Jeon, J Pevsner, M E Blue, S Naid. Neurobiology of Rett syndrome: a genetic disorder of synapse development. Brain & development. vol 23 Suppl 1. 2002-03-13. PMID:11738874. |
in a study of amino acid neurotransmitter receptors using receptor autoradiography in tissue slices of frontal cortex and the basal ganglia, we found a biphasic age-related pattern with relatively high receptor densities in young rs girls and lower densities at later time. |
2002-03-13 |
2023-08-12 |
Not clear |
| S V Argyropoulos, C J Bell, D J Nut. Brain function in social anxiety disorder. The Psychiatric clinics of North America. vol 24. issue 4. 2002-02-20. PMID:11723629. |
the best evidence for neurotransmitter abnormality so far is for altered dopamine function at the level of the basal ganglia, either pre- or postsynaptic, which may result in reduced basal ganglia function so that the normal fluidity of social motor functions (e.g., smiling, eye movements, and speech) are impaired, thus leading to the cognitive symptoms of social anxiety and the subsequent generation of avoidance behavior. |
2002-02-20 |
2023-08-12 |
Not clear |
| C Schwarzer, U Berresheim, S Pirker, A Wieselthaler, K Fuchs, W Sieghart, G Sper. Distribution of the major gamma-aminobutyric acid(A) receptor subunits in the basal ganglia and associated limbic brain areas of the adult rat. The Journal of comparative neurology. vol 433. issue 4. 2001-06-28. PMID:11304716. |
within the basal ganglia, gamma-aminobutyric acid (gaba) exerts a fundamental role as neurotransmitter of local circuit and projection neurons. |
2001-06-28 |
2023-08-12 |
rat |
| J M Henderson, K Carpenter, H Cartwright, G M Hallida. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain : a journal of neurology. vol 123 ( Pt 7). 2000-08-07. PMID:10869053. |
these findings indicate that dysregulation of two neurotransmitter systems within the basal ganglia may underlie common parkinsonian symptoms in these disorders. |
2000-08-07 |
2023-08-12 |
Not clear |
| L Y Moy, G D Zeevalk, P K Sonsall. Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures. Journal of neurochemistry. vol 74. issue 4. 2000-04-11. PMID:10737624. |
in addition, the reactive metabolites generated from the metabolism and oxidation of the neurotransmitter dopamine (da) are thought to contribute to the damage to neurons of the basal ganglia. |
2000-04-11 |
2023-08-12 |
mouse |
| C M Kosinski, S Risso Bradley, P J Conn, A I Levey, G B Landwehrmeyer, J B Penney, A B Young, D G Standaer. Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia. The Journal of comparative neurology. vol 415. issue 2. 1999-12-10. PMID:10545164. |
the presence of mglur7 at these multiple sites in the basal ganglia suggests that this receptor has a particularly crucial role in modulating neurotransmitter release in major basal ganglia pathways. |
1999-12-10 |
2023-08-12 |
rat |
| M Chanimov, M Bahar, M L Cohen, R Brenner, I Koifman, Y Grinshpo. Spinal anaesthesia with gamma hydroxybutyrate. A study in a rat model. European journal of anaesthesiology. vol 16. issue 5. 1999-08-17. PMID:10390669. |
gamma hydroxybutyric acid, a central inhibitory neurotransmitter and a cerebral metabolite of gamma-aminobutyric acid, is present in high concentrations in the mammalian hypothalamus and basal ganglia. |
1999-08-17 |
2023-08-12 |
rat |
| M Vila, C Marin, M Ruberg, A Jimenez, R Raisman-Vozari, Y Agid, E Tolosa, E C Hirsc. Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia. Journal of neurochemistry. vol 73. issue 1. 1999-07-08. PMID:10386987. |
because the subthalamic nucleus uses glutamate as neurotransmitter and is innervated by glutamatergic fibers, pharmacological blockade of glutamate transmission might be expected to restore the cascade of neurochemical changes induced by a dopaminergic denervation within the basal ganglia. |
1999-07-08 |
2023-08-12 |
rat |
| B Gallhofer, S Lis, A Meyer-Lindenberg, S Kriege. Cognitive dysfunction in schizophrenia: a new set of tools for the assessment of cognition and drug effects. Acta psychiatrica Scandinavica. Supplementum. vol 395. 1999-06-28. PMID:10225341. |
cognitive impairment in schizophrenia must be seen as a disturbance of cortico-sub-cortical connectivity with a neurotransmitter imbalance in a circuitry system, which connects thalamic input with prefrontal processing and supplementary motor cortex and basal ganglia output. |
1999-06-28 |
2023-08-12 |
Not clear |
| b' M Casas, G Prat, P Robledo, M Barbanoj, J Kulisevsky, F Jan\\xc3\\xa. Scopolamine prevents tolerance to the effects of caffeine on rotational behavior in 6-hydroxydopamine-denervated rats. European journal of pharmacology. vol 366. issue 1. 1999-04-14. PMID:10064145.' |
the results are interpreted in terms of the possible interactions between dopamine, adenosine and acetylcholine neurotransmitter systems within the basal ganglia circuitry involved in motor behavior. |
1999-04-14 |
2023-08-12 |
rat |
| M C Sañudo-Peña, J M Walke. A novel neurotransmitter system involved in the control of motor behavior by the basal ganglia. Annals of the New York Academy of Sciences. vol 860. 1999-02-18. PMID:9928344. |
a novel neurotransmitter system involved in the control of motor behavior by the basal ganglia. |
1999-02-18 |
2023-08-12 |
Not clear |
| D J Eve, A P Nisbet, A E Kingsbury, E L Hewson, S E Daniel, A J Lees, C D Marsden, O J Foste. Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Brain research. Molecular brain research. vol 63. issue 1. 1999-01-21. PMID:9838046. |
these findings provide evidence of increased activity of stn neurotransmitter systems in pd and demonstrate for the first time in any species that basal ganglia nitric oxide systems can be selectively regulated in response to changes in dopaminergic input. |
1999-01-21 |
2023-08-12 |
human |
| J L Janavs, M J Aminof. Dystonia and chorea in acquired systemic disorders. Journal of neurology, neurosurgery, and psychiatry. vol 65. issue 4. 1998-11-10. PMID:9771763. |
hypoxia-ischaemia may injure the basal ganglia through hypoperfusion of subcortical vascular watershed regions and by altering striatal neurotransmitter systems. |
1998-11-10 |
2023-08-12 |
Not clear |
| J L Janavs, M J Aminof. Dystonia and chorea in acquired systemic disorders. Journal of neurology, neurosurgery, and psychiatry. vol 65. issue 4. 1998-11-10. PMID:9771763. |
endocrine and electrolyte abnormalities influence neurotransmitter balance or affect ion channel function and signalling in the basal ganglia. |
1998-11-10 |
2023-08-12 |
Not clear |
| J L Contreras-Vidal, P Poluha, H L Teulings, G E Stelmac. Neural dynamics of short and medium-term motor control effects of levodopa therapy in Parkinson's disease. Artificial intelligence in medicine. vol 13. issue 1-2. 1998-09-24. PMID:9654379. |
short and long-term dynamics of cell activations and neurotransmitter mechanisms underlying the differential expression of neuropeptide messenger rna within the basal ganglia striatum are modeled to provide a mechanistic account for the effects of levodopa medication on motor performance (e.g. |
1998-09-24 |
2023-08-12 |
human |